ArticleBioactive materials2027
Click chemistry-modified cardiomyocytes enhance cardiac contractility and prevent remodeling in ischemia-reperfusion injured hearts.
Article in Bioactive materials, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the challenges in cardiac cell therapy using cardiomyocytes derived from human pluripotent stem cells (hPSC-CMs) is their poor engraftment and survival rate in infarcted tissues. Click chemistry and lipid insertion are simple methods for modifying the surface of hPSC-CMs with a collagen hybridizing peptide (CHP), providing binding motifs to increase their retention and engraftment in fibrotic hearts after ischemia-reperfusion (I/R) injury. In this study, we developed CHP-modified CMs (CHP-mCMs) to attach cells to damaged collagen in infarcted tissues. We injected CHP-mCMs into the border zone of infarcted hearts 7 days post-MI and evaluated cardiac function for 6 weeks. Serial echocardiography revealed that CHP-mCMs not only improved cardiac function but also reduced adverse remodeling in I/R-injured hearts. These findings indicate that CHP-mCM transplantation was associated with enhanced engraftment, reduced adverse remodeling, and improved cardiac function in the rat I/R model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.